bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Authors: Bhagirath Divya , Yang Thao Ly , Tabatabai Z. Laura , Majid Shahana , Dahiya Rajvir , Tanaka Yuichiro , Saini Sharanjot
Published: April 2023

Fig. S2 Correlation of EV-associated BRN4 and BRN2 with clinicopathological parameters of mCRPC
Supplementary Data from Quantitative Ultrasound Spectroscopy for Differentiation of Hepatocellular Carcinoma from At-Risk and Normal Liver Parenchyma
Authors: Durot Isabelle , Sigrist Rosa M.S. , Kothary Nishita , Rosenberg Jarrett , Willmann Jürgen K. , El Kaffas Ahmed
Published: April 2023

Supplementary Figures
Table S1 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S1 shows the patient characteristics of clinical samples.
Supplemental Table S2 from FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Authors: Krauss Aviva C. , Gao Xin , Li Liang , Manning Michael L. , Patel Paresma , Fu Wentao , Janoria Kumar G. , Gieser Gerlie , Bateman David A. , Przepiorka Donna , Shen Yuan Li , Shord Stacy S. , Sheth Christopher M. , Banerjee Anamitro , Liu Jiang , Goldberg Kirsten B. , Farrell Ann T. , Blumenthal Gideon M. , Pazdur Richard
Published: April 2023

Supplemental Table 2: Prolonged Cytopenia on Study 301
Supplemental Table S1 from FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Authors: Krauss Aviva C. , Gao Xin , Li Liang , Manning Michael L. , Patel Paresma , Fu Wentao , Janoria Kumar G. , Gieser Gerlie , Bateman David A. , Przepiorka Donna , Shen Yuan Li , Shord Stacy S. , Sheth Christopher M. , Banerjee Anamitro , Liu Jiang , Goldberg Kirsten B. , Farrell Ann T. , Blumenthal Gideon M. , Pazdur Richard
Published: April 2023

Supplemental Table S1: Grouped Terms for Adverse Reactions on Study 301
Figure S7 from IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Authors: Conlon Kevin C. , Potter E. Lake , Pittaluga Stefania , Lee Chyi-Chia Richard , Miljkovic Milos D. , Fleisher Thomas A. , Dubois Sigrid , Bryant Bonita R. , Petrus Michael , Perera Liyanage P. , Hsu Jennifer , Figg William D. , Peer Cody J. , Shih Joanna H. , Yovandich Jason L. , Creekmore Stephen P. , Roederer Mario , Waldmann Thomas A.
Published: April 2023

Supplementary Figure S7
Supplementary Table 1 from Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
Authors: Rashid Naim U. , Peng Xianlu L. , Jin Chong , Moffitt Richard A. , Volmar Keith E. , Belt Brian A. , Panni Roheena Z. , Nywening Timothy M. , Herrera Silvia G. , Moore Kristin J. , Hennessey Sarah G. , Morrison Ashley B. , Kawalerski Ryan , Nayyar Apoorve , Chang Audrey E. , Schmidt Benjamin , Kim Hong Jin , Linehan David C. , Yeh Jen Jen
Published: April 2023

Table S1
Supplementary Data from An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option
Authors: Manzotti Gloria , Torricelli Federica , Benedetta Donati , Lococo Filippo , Sancisi Valentina , Rossi Giulio , Piana Simonetta , Ciarrocchi Alessia
Published: April 2023

Supplementary Figure 1 A) Genes included in the panel. B) Distribution of 57 somatic mutation events detected in the PSCs according to the functional consequence of nucleotides substitution. C) Frequency of mutated samples for each gene.
Supplementary Data from An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option
Authors: Manzotti Gloria , Torricelli Federica , Benedetta Donati , Lococo Filippo , Sancisi Valentina , Rossi Giulio , Piana Simonetta , Ciarrocchi Alessia
Published: April 2023

Supplementary Figure 2 A) Dot-Â­Â€�plot representation of ECAD expression in E and S component of analyzed PSCs. Positivity score represents % of ECAD positive cells. B) Representative ECAD staining showing both E and S components. Magnification 200X. Insert Magnification 400X. C) Nanostring Expression of EMT-Â­Â€� associated TFs in NSCLCs as compared to vE samples in the validation set. Histogram represents normalized mean counts +/-Â­Â€� SEM. D) Principal Component Analysis gene expression signature based on S-Â­Â€�component histology. E) qRT-Â­Â€�PCR analysis of E and S associated markers in H1975, H1650 and H1299 (NSCLC cell lines). F-Â­Â€� G )q RT-Â­Â€�PCR and WB evaluation of OVOL2 silencing in H1975. H) qRT-Â­Â€� PCR of E and S associated genes in H1975 cells transfected with siOVOL2 or siCtrl cells 48h and 72h after transfection. Histograms represent the relative fold change +/-Â­Â€� SD of these genes in OVOL2 silenced cells as compared to control cells (set as 1, black line). Each experiment represents the average of at least two independent replicate. * p< 0.05.
Supplementary Data from An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option
Authors: Manzotti Gloria , Torricelli Federica , Benedetta Donati , Lococo Filippo , Sancisi Valentina , Rossi Giulio , Piana Simonetta , Ciarrocchi Alessia
Published: April 2023

Supplementary Figure 3 A) H1299 were treated with Dasatinib in a concentration range between 0,01uM and 0,5uM for 48h and IC50 and IC70 were calculated with GraphPad. B) Growth curve of H1299, H1650 and H1975 treated with 0.2uM dasatinib or Mock. C) Growth curve of H1299, H1650 and H1975 treated with 0.5uM Cisplatin or Mock. Curves represent the number of cells +/-Â­Â€�SD for each condition at the indicated time points, relatively to mock. Each experiment represents the average of at least two independent replicate. * p< 0.05. D) qRT-Â­Â€�PCR of EMT TFs and markers after 48h of dasatinib treatment in H1299. Histograms represent the relative fold change +/-Â­Â€� SEM of treated cells as compared to control cells of a representative experiment. Each experiment represents the average of at least two independent replicate. * p< 0.05. E) Light microscopy images of H1299 treated with Dasatinib or with Mock for 48h. Magnification 400X. F) Effects of Dasatinib on DDR2 were checked by immunoprecipitation of total exctract with anti-Â­Â€�phospho-Â­Â€�Tyrosine antibody and a subsequent blot with anti-Â­Â€�DDR2 antibody. (G-Â­Â€�I) H1299 DDR2 KD clones were screened for ALT-Â­Â€�R (G) %Indel (H),and their levels of DDR2 protein (I).
Table S2 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Authors: Walsh Louise , Haley Kathryn E. , Moran Bruce , Mooney Brian , Tarrant Finbarr , Madden Stephen F. , Di Grande Alessandra , Fan Yue , Das Sudipto , Rueda Oscar M. , Dowling Catríona M. , Varešlija Damir , Chin Suet-Feung , Linn Sabine , Young Leonie S. , Jirström Karin , Crown John P. , Bernards Rene , Caldas Carlos , Gallagher William M. , O'Connor Darran P. , Ní Chonghaile Tríona
Published: April 2023

Table S2: Primer List
Figure S1 from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Authors: Alvarez Secord Angeles , Bell Burdett Kirsten , Owzar Kouros , Tritchler David , Sibley Alexander B. , Liu Yingmiao , Starr Mark D. , Brady J. Chris , Lankes Heather A. , Hurwitz Herbert I. , Mannel Robert S. , Tewari Krishnansu S. , O'Malley David M. , Gray Heidi , Bakkum-Gamez Jamie N. , Fujiwara Keiichi , Boente Matthew , Deng Wei , Burger Robert A. , Birrer Michael J. , Nixon Andrew B.
Published: April 2023

Flow diagram of patients through the study.
Supplementary Data from Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer
Authors: Annels Nicola E. , Mansfield David , Arif Mehreen , Ballesteros-Merino Carmen , Simpson Guy R. , Denyer Mick , Sandhu Sarbjinder S. , Melcher Alan A. , Harrington Kevin J. , Davies Bronwyn , Au Gough , Grose Mark , Bagwan Izhar , Fox Bernard , Vile Richard , Mostafid Hugh , Shafren Darren , Pandha Hardev S.
Published: April 2023

Supplementary data - revised
Supplementary Tables from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Authors: Kim Kyung Hwan , Cho Jinhyun , Ku Bo Mi , Koh Jiae , Sun Jong-Mu , Lee Se-Hoon , Ahn Jin Seok , Cheon Jaekyung , Min Young Joo , Park Su-Hyung , Park Keunchil , Ahn Myung-Ju , Shin Eui-Cheol
Published: April 2023

Supplementary Tables S1-S7
Supplementary figures from Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells
Authors: Mota Reyes Carmen , Teller Steffen , Muckenhuber Alexander , Konukiewitz Björn , Safak Okan , Weichert Wilko , Friess Helmut , Ceyhan Güralp O. , Demir Ihsan Ekin
Published: April 2023

Supplementary Figure 1. Object-based automated detection analysis of immune cell infiltration in human PCa with CellProfiler Software. Supplementary Figure 2. Automated analysis of the angiogenesis and stromal activation in PCa. Supplementary Figure 3. Automated quantification of neurogenesis, neural invasion and tumor proliferation rate in human PCa. Supplementary Figure 4. Histopathological impact of the applied pre-treatment: Gemcitabine-based therapy vs Folfirinox vs Radiochemotherapy (RTx). Supplementary Figure 5. Correlation analysis between tumor index and tumor-infiltrating immune cells, desmoplastic reaction and neural invasion. Supplementary Figure 6. Correlation analysis between ASI and tumor-infiltrating immune cells. Supplementary Figure 7. Correlation analysis between cytotoxic T cells (A, B) and Treg ratios (C,D) with angiogenesis. Supplementary Figure 8. Impact of neoTx on neurogenesis and its correlation with stromal activity. Supplementary Figure 9. Survival analysis of PCa patients based on clinical features. Supplementary Figure 10. Spatial distribution of the components of the tumor microenvironment according to the anatomical location of the tumor. Supplementary Figure 11. Immunological effects of NeoCTx in human PCa. (A) PCa-mediated immunosuppresive tumor microenvironment.
Supplementary Table S1-S2 from Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Authors: Mitani Yoshitsugu , Lin Sue-Hwa , Pytynia Kristen B. , Ferrarotto Renata , El-Naggar Adel K.
Published: April 2023

Supplementary Table S1. Significant expression differences between AR and control siRNAs treatment in RET981 cell. Supplementary Table S2. PCR Primer information
Table S5 from Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Authors: Groot Vincent P. , Mosier Stacy , Javed Ammar A. , Teinor Jonathan A. , Gemenetzis Georgios , Ding Ding , Haley Lisa M. , Yu Jun , Burkhart Richard A. , Hasanain Alina , Debeljak Marija , Kamiyama Hirohiko , Narang Amol , Laheru Daniel A. , Zheng Lei , Lin Ming-Tseh , Gocke Christopher D. , Fishman Elliot K. , Hruban Ralph H. , Goggins Michael G. , Molenaar I. Quintus , Cameron John L. , Weiss Matthew J. , Velculescu Victor E. , He Jin , Wolfgang Christopher L. , Eshleman James R.
Published: April 2023

Serial Dilution Data
Supplementary Information from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
Authors: Motea Edward A. , Huang Xiumei , Singh Naveen , Kilgore Jessica A. , Williams Noelle S. , Xie Xian-Jin , Gerber David E. , Beg Muhammad S. , Bey Erik A. , Boothman David A.
Published: April 2023

Supplemental Information
Figure S8 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Data from The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Authors: Knepper Todd C. , Montesion Meagan , Russell Jeffery S. , Sokol Ethan S. , Frampton Garrett M. , Miller Vincent A. , Albacker Lee A. , McLeod Howard L. , Eroglu Zeynep , Khushalani Nikhil I. , Sondak Vernon K. , Messina Jane L. , Schell Michael J. , DeCaprio James A. , Tsai Kenneth Y. , Brohl Andrew S.
Published: April 2023

Figure S4
Figure S11 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Data from Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Authors: Pairawan Seyed , Hess Kenneth R. , Janku Filip , Sanchez Nora S. , Mills Shaw Kenna R. , Eng Cathy , Damodaran Senthilkumar , Javle Milind , Kaseb Ahmed O. , Hong David S. , Subbiah Vivek , Fu Siqing , Fogelman David R. , Raymond Victoria M. , Lanman Richard B. , Meric-Bernstam Funda
Published: April 2023

Supplemental Tables 1, 2, 3 and Supplemental Figure 1
Supplementary Material from Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy
Authors: Trendowski Matthew R. , El-Charif Omar , Ratain Mark J. , Monahan Patrick , Mu Zepeng , Wheeler Heather E. , Dinh Paul C. , Feldman Darren R. , Ardeshir-Rouhani-Fard Shirin , Hamilton Robert J. , Vaughn David J. , Fung Chunkit , Kollmannsberger Christian , Mushiroda Taisei , Kubo Michiaki , Hannigan Robyn , Strathmann Frederick , Einhorn Lawrence H. , Fossa Sophie D. , Travis Lois B. , Dolan M. Eileen
Published: April 2023

Supplemental Figures and Tables Supplemental Figure 1. GWAS and Quality Control Pipeline. Abbreviations: IBD: identity by descent; SD: standard deviation; MAF: minor allele frequency. Supplemental Table 1. Additional Clinical and Sociodemographic Characteristics for 1,010 Testicular Cancer Survivors According to Residual Platinum Values. Supplemental Table 2. Univariate Multinomial Regression of the Association Between Residual Platinum Values and Clinical Phenotypes Relevant to Cisplatin-Based Chemotherapy. Supplemental Table 3. Multinomial Regression of the Association Between Residual Platinum Values and Phenotypes Relevant to Cisplatin-Based Chemotherapy with Age at Diagnosis as a Covariate. Supplemental Table 4. GWAS Results (P < 0.0001).
Supplementary Data Figures from Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas
Authors: Unruh Dusten , Mirkov Snezana , Wray Brian , Drumm Michael , Lamano Jonathan , Li Yuping D. , Haider Qazi F. , Javier Rodrigo , McCortney Kathleen , Saratsis Amanda , Scholtens Denise M. , Sarkaria Jann N. , James C. David , Horbinski Craig
Published: April 2023

Supplementary data figures
Supplementary Figure S2 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study
Authors: Buus Richard , Sestak Ivana , Barron Stephen , Loughman Tony , Fender Bozena , Ruiz Cesar Lopez , Dynoodt Peter , Wang Chan-Ju Angel , O'Leary Des , Gallagher William M. , Dowsett Mitch , Cuzick Jack
Published: April 2023

Scatterplots of OncoMasTR Molecular Score and normalised expression of three genes constituting it based on RNA extracted by GHI and OncoMark from 108 TransATAC samples. Pearson's r and p-value are also presented.
Figure S2 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Authors: Henderson Meredith C. , Silver Michael , Tran Quynh , Letsios Elias E. , Mulpuri Rao , Reese David E. , Lourenco Ana P. , LaBaer Joshua , Anderson Karen S. , Alpers Josie , Costantini Carrie , Rohatgi Nitin , Ali Haythem , Baker Karen , Northfelt Donald W. , Ghosh Karthik , Grobmyer Stephen R. , Polen Winnie , Wolf Judith K.
Published: April 2023

Figure S2: Clinical management workflow with inclusion/exclusion criteria for the PDX-002 clinical trial. *Details on malignancy risk from D'Orsi et al.[3]
Table S5 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S5
Table S4 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S4
Figure from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

DNA methyltransferase DNMT1 suppresses RIPK3 transcription. A, Immunoblot analysis of MM cells with knockdown of DNMT1 protein (184 kDa) expression. RIPK3-negative cells were transfected with two siRNAs against DNMT1 or an siControl (siCon), and DNMT1 protein levels were determined by immunoblot analysis 72 hours post-transfection. B, Semi-quantitative RT-PCR to detect knockdown of DNMT1 (500 bp), re-expression of RIPK3 (700 bp), as well as expression of control GAPDH (800 kDa).
Supplementary Figures from Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Authors: Talhouk Aline , Derocher Heather , Schmidt Pascal , Leung Samuel , Milne Katy , Gilks C. Blake , Anglesio Michael S. , Nelson Brad H. , McAlpine Jessica N.
Published: April 2023

Supplementary Figures S1-S3
Supplementary Tables from CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy
Authors: Kimura Hirokazu , Yamamoto Hideki , Harada Takeshi , Fumoto Katsumi , Osugi Yoshihito , Sada Ryota , Maehara Natsumi , Hikita Hayato , Mori Soichiro , Eguchi Hidetoshi , Ikawa Masahito , Takehara Tetsuo , Kikuchi Akira
Published: April 2023

List of cell lines used in this study (Table S1). List of antibodies and other chemicals used in this study (Table S2). Target sequences for siRNA used in this study (Table S3). Primer sequences for quantitative PCR used in this study (Table S4). The peptide sequences recognized by anti-CKAP4 mAbs (Table S5).
Supplementary Figure 1 from Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
Authors: Soliman Pamela T. , Westin Shannon N. , Iglesias David A. , Fellman Bryan M. , Yuan Ying , Zhang Qian , Yates Melinda S. , Broaddus Russell R. , Slomovitz Brian M. , Lu Karen H. , Coleman Robert L.
Published: April 2023

Supplementary Figure S1
Supplementary Data 1 from Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
Authors: Eberst Guillaume , Anota Amélie , Scherpereel Arnaud , Mazieres Julien , Margery Jacques , Greillier Laurent , Audigier-Valette Clarisse , Moro-Sibilot Denis , Molinier Olivier , Léna Hervé , Rivière Frédéric , Monnet Isabelle , Gounant Valérie , Janicot Henri , Gervais Radj , Locher Chrystelle , Charton Emilie , Morin Franck , Zalcman Gérard , Westeel Virginie
Published: April 2023

Table 1
Supplementary Data from Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer
Authors: Thorek Daniel L.J. , Ku Anson T. , Mitsiades Nicholas , Veach Darren , Watson Philip A. , Metha Dipti , Strand Sven-Erik , Sharma Sai Kiran , Lewis Jason S. , Abou Diane S. , Lilja Hans G. , Larson Steven M. , McDevitt Michael R. , Ulmert David
Published: April 2023

Supplementary figure 1
Figure S3 from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers
Authors: Nevler Avinoam , Muller Alexander J. , Sutanto-Ward Erika , DuHadaway James B. , Nagatomo Kei , Londin Eric , O'Hayer Kevin , Cozzitorto Joseph A. , Lavu Harish , Yeo Theresa P. , Curtis Mark , Villatoro Tatiana , Leiby Benjamin E. , Mandik-Nayak Laura , Winter Jordan M. , Yeo Charles J. , Prendergast George C. , Brody Jonathan R.
Published: April 2023

Supplemental survival data (color line graphs)
Figure S11 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 11. Mutation detection between primary tissue and later cfDNA collections in patient P09.
Supplementary Data from A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ
Authors: Mittal Karuna , Toss Michael S. , Wei Guanhao , Kaur Jaspreet , Choi Da Hoon , Melton Brian D. , Osan Remus M. , Miligy Islam M. , Green Andrew R. , Janssen Emiel A.M. , Søiland Håvard , Gogineni Keerthi , Manne Upender , Rida Padmashree , Rakha Emad A. , Aneja Ritu
Published: April 2023

Supplementary Data
Supplementary Figure 3 from Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Ryu Daeun , Kim Seok Jin , Hong Yourae , Jo Areum , Kim Nayoung , Kim Hee-Jin , Lee Hae-Ock , Kim Kihyun , Park Woong-Yang
Published: April 2023

Gene expression features of myeloma cells.
Supplementary Data from Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Authors: Luke Jason J. , Olson Daniel J. , Allred Jacob B. , Strand Carrie A. , Bao Riyue , Zha Yuanyuan , Carll Timothy , Labadie Brian W. , Bastos Bruno R. , Butler Marcus O. , Hogg David , Munster Pamela N. , Schwartz Gary K.
Published: April 2023

This includes Supplementary Table 1 with all adverse events by arm. Supplementary Figure 1 shows best overall response in patients with restaging imaging. Supplementary Figure 2 shows all somatic mutations, including those identified in an exploratory fashion.
Supplementary Data and Figures from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Authors: Xu Jianming , Zhang Yun , Jia Ru , Yue Chunyan , Chang Lianpeng , Liu Rongrui , Zhang Gairong , Zhao Chuanhua , Zhang Yaoyue , Chen Chunxia , Wang Yan , Yi Xin , Hu Zhiyuan , Zou Jianjun , Wang Quanren
Published: April 2023

1. Inclusion and Exclusion Criteria 2. Study endpoint definitions 3. Appendix Table 1 4. Appendix Figure Legends 5. Method of TMB Analysis
Supplementary Table S5. Literature Review - Efficacy Outcomes by Binary MRD Level for B-cell ALL from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Authors: Jen Emily Y. , Xu Qing , Schetter Aaron , Przepiorka Donna , Shen Yuan Li , Roscoe Donna , Sridhara Rajeshwari , Deisseroth Albert , Philip Reena , Farrell Ann T. , Pazdur Richard
Published: April 2023

Literature review - efficacy by binary MRD outcome
Figure S5 from Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer
Authors: Karasinska Joanna M. , Topham James T. , Kalloger Steve E. , Jang Gun Ho , Denroche Robert E. , Culibrk Luka , Williamson Laura M. , Wong Hui-Li , Lee Michael K.C. , O'Kane Grainne M. , Moore Richard A. , Mungall Andrew J. , Moore Malcolm J. , Warren Cassia , Metcalfe Andrew , Notta Faiyaz , Knox Jennifer J. , Gallinger Steven , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Renouf Daniel J. , Schaeffer David F.
Published: April 2023

Kaplan-Meier curve demonstrating the differences in the time to relapse in resectable PDAC. Data for ICGC PACA-CA cohort with available relapse data are shown (N=118).
Figure S1 from Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer
Authors: Karasinska Joanna M. , Topham James T. , Kalloger Steve E. , Jang Gun Ho , Denroche Robert E. , Culibrk Luka , Williamson Laura M. , Wong Hui-Li , Lee Michael K.C. , O'Kane Grainne M. , Moore Richard A. , Mungall Andrew J. , Moore Malcolm J. , Warren Cassia , Metcalfe Andrew , Notta Faiyaz , Knox Jennifer J. , Gallinger Steven , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Renouf Daniel J. , Schaeffer David F.
Published: April 2023

Scatter plot depicting principal component analysis of the top 25% most variable genes across the integrated cohort of resectable and advanced PDACs before (left) and after (right) batch correction.
Figure S6 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Authors: Wang Sabrina Z. , Poore Brad , Alt Jesse , Price Antoinette , Allen Sariah J. , Hanaford Allison R. , Kaur Harpreet , Orr Brent A. , Slusher Barbara S. , Eberhart Charles G. , Raabe Eric H. , Rubens Jeffrey A.
Published: April 2023

Formal synergy studies with DON and carboplatin
Figure S1 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Authors: Wang Sabrina Z. , Poore Brad , Alt Jesse , Price Antoinette , Allen Sariah J. , Hanaford Allison R. , Kaur Harpreet , Orr Brent A. , Slusher Barbara S. , Eberhart Charles G. , Raabe Eric H. , Rubens Jeffrey A.
Published: April 2023

Cellular proliferation in high vs low MYC AT/RT cell lines
Figure S1 from Detection of NRG1 Gene Fusions in Solid Tumors
Authors: Jonna Sushma , Feldman Rebecca A. , Swensen Jeffrey , Gatalica Zoran , Korn Wolfgang M. , Borghaei Hossein , Ma Patrick C. , Nieva Jorge J. , Spira Alexander I. , Vanderwalde Ari M. , Wozniak Antoinette J. , Kim Edward S. , Liu Stephen V.
Published: April 2023

Figure S1 from Detection of NRG1 Gene Fusions in Solid Tumors
Supplementary Data from Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma
Authors: Desmots Fabienne , Roussel Mikaël , Pangault Céline , Llamas-Gutierrez Francisco , Pastoret Cédric , Guiheneuf Eric , Le Priol Jérôme , Camara-Clayette Valérie , Caron Gersende , Henry Catherine , Belaud-Rotureau Marc-Antoine , Godmer Pascal , Lamy Thierry , Jardin Fabrice , Tarte Karin , Ribrag Vincent , Fest Thierry
Published: April 2023

Figure S1 : (A) The 1769-genes signature corresponding to CB/CC transition and CB response to IL-21/CD40L co-stimulation and that are differentially expressed in FL compared to CC and CB were explored using Ingenuity Pathway Analysis (IPA). IPA enrichment analysis showed that these genes are mainly involved in CD40L signaling and IPA diagram highlight activated pathway including NF-KappaB (Nuclear Factor-KappaB), MAPK (Mitogen-Activated Protein Kinase) and STAT3 (Signal Transducers and Activators of Transcription-3). This observation suggests that FL-tumor cells can respond to the Il- 21/CD40L signaling. (B) Modulation of gene expression in CB compared to FL during CB/CC transition related to CD40L+IL-21 stimulation was explored by geneset enrichment assays (GSEA) using signatures available on MSigDB: M8493 for CD40 up-regulated genes, M2827 for IL-21 up-regulated genes, M4552 for up-regulated genes in plasma cells. (C) BLIMP-1 immnunostaining performed on multiple myeloma (1), reactive lymph node (2) and follicular lymphoma (3) gives strong, weak (very few positive cells) and negative signal respectively, using the PRDM1 antibody (3H2-E8) from Thermo Scientific. Figure S2: Burkitt lymphoma-derived L3055 cell line characteristics. Figure S3: Purity and viability of FL B-cell fractions. Figure S4: Visualization of gating strategy of a representative sample. Figure S5 : BCL6 binding analysis on Intron 3 of PRDM1 gene. Figure S6: Detection of PRDM1 mRNA and BLIMP1 protein in unstimulated or treated L3055 cells. Figure S7 : FL B cell number for each fraction and percentage of cell viability in each cell culture condition (N=6). Figure S8 : Uncropped original images of immunoblots. Table S1 : Top-20 pathways associated with 804-upregulated (upper panel) or 967-downregulated genes (lower panel). Table S2: Clinical data and somatic mutations for epigenetic genes - CREBBP, EP300, EZH2, KMT2D & MEF2B - in the 20 FLs of the cohort. Table S3: Available clinical data and somatic mutations found in genes designed in the lymphopanel for the 4 patients with a refractory or multiple relapsing FL tested for the oral administration of the HDACi treatment. Table S5: List of primers used for quantitative RQ-PCR and QChIP-PCR
Tables S5-S13 from The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Authors: Law Henry C.-H. , Lagundžin Dragana , Clement Emalie J. , Qiao Fangfang , Wagner Zachary S. , Krieger Kimiko L. , Costanzo-Garvey Diane , Caffrey Thomas C. , Grem Jean L. , DiMaio Dominick J. , Grandgenett Paul M. , Cook Leah M. , Fisher Kurt W. , Yu Fang , Hollingsworth Michael A. , Woods Nicholas T.
Published: April 2023

Table S5: The protein expression matrix used for input in the Principle Component Analysis. Table S6: The list of gene ontology terms in each cluster observed in the SAFE network. Table S7: The regression coefficients and constants of each protein in each proteomics subtype in the Partial Least Squares-Discriminant Analysis. Table S8: The gene ontology analysis of Protein Cluster 1 from ClueGO. Table S9: The gene ontology analysis of Protein Cluster 2 from ClueGO. Table S10: The gene ontology analysis of Protein Cluster 3 from ClueGO. Table S11: The Reactome pathway enrichment analysis on the average protein expression of the 4 proteomics subtypes. Table S12: The tertile assignments of each of the 916 proteins used for the analysis in each 56 samples. Table S13: The comparative analysis of the gemcitabine-treated proteome.
Supplementary Video S5 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S5
Supplementary Methods from Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness
Authors: Molina-Crespo Ángela , Cadete Ana , Sarrio David , Gámez-Chiachio Manuel , Martinez Lidia , Chao Kinlin , Olivera Ana , Gonella Andrea , Díaz Eva , Palacios José , Dhal Pradeep K. , Besev Magnus , Rodríguez-Serrano Macarena , García Bermejo María Laura , Triviño Juan Carlos , Cano Amparo , García-Fuentes Marcos , Herzberg Osnat , Torres Dolores , Alonso Maria José , Moreno-Bueno Gema
Published: April 2023

Supplementary Methods, References and Table 1
Supplementary Table 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Table 3: Spearman's rho correlation coefficients of MRC vs clinicopathological risk factors for all the clinical cohorts.
Table S8 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

List of dysregulated pathways between patients with higher and lower expression of DOCK5 variant in TCGA HPV negative HNSCC data
Supplementary Figure 1 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Figure 1: Recurrence prediction comparison between CMS and MRC in the A) TCGA discovery and B) Validation cohorts.
Figure S1-5 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

Figure S1:Distribution of ASEs present within each tumor in TCGA HPV negative HNSCC cohort. Figure S2: Expression of DOCK5 variant within different head and neck regions. Figure S3: Relationship between DOCK5 variant expression and gene mutation. Figure S4: DOCK5 variant expression in HPV negative HNSCC cell lines. Figure S5: Differentially expressed gene and pathway analysis.
Supplementary Table S7 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

(Table S7A) The frequency and pattern of ERBB2 compound mutations. (Table S7B) ERRB2 compound mutations and cancer types.
Supplementary Table S6 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Fig. 3B.
Supplementary Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Authors: Cowman Sophie J. , Fuja Daniel G. , Liu Xian-De , Tidwell Rebecca S. Slack , Kandula Neelima , Sirohi Deepika , Agarwal Archana M. , Emerson Lyska L. , Tripp Sheryl R. , Mohlman Jeffrey S. , Stonhill Miekan , Garcia Guillermina , Conley Christopher J. , Olalde Adam A. , Sargis Timothy , Ramirez-Torres Adela , Karam Jose A. , Wood Christopher G. , Sircar Kanishka , Tamboli Pheroze , Boucher Kenneth , Maughan Benjamin , Spike Benjamin T. , Ho Thai H. , Agarwal Neeraj , Jonasch Eric , Koh Mei Yee
Published: April 2023

Supplemental Tables
Supplementary Figure S2 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Authors: Higgs Brandon W. , Morehouse Christopher A. , Streicher Katie , Brohawn Philip Z. , Pilataxi Fernanda , Gupta Ashok , Ranade Koustubh
Published: April 2023

Supplemental Figure S2. Association of IFNγ+ signature with ORR at higher cutoffs in NSCLC and UC patients.
Figure S2 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Figure S2
Supplementary Table S4 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

PKPD data utilized to establish the level and duration of target inhibition required for AZD3229
Supplementary Figure S1 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Graphical description of the PKPD model used to describe effects of AZD3229 in mouse tumor models
Figure S2 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Institutional management guidelines for NT adapted from the CARTOX working group criteria.
Figure S4 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Authors: Narasimhan Vignesh , Wright Josephine A. , Churchill Michael , Wang Tongtong , Rosati Rachele , Lannagan Tamsin R.M. , Vrbanac Laura , Richardson Anne B. , Kobayashi Hiroki , Price Timothy , Tye Gayle X.Y. , Marker Julie , Hewett Peter J. , Flood Michael P. , Pereira Shalini , Whitney G. Adam , Michael Michael , Tie Jeanne , Mukherjee Siddhartha , Grandori Carla , Heriot Alexander G. , Worthley Daniel L. , Ramsay Robert G. , Woods Susan L.
Published: April 2023

Peritonoid sensitivity to standard care chemotherapeutic regimens ex vivo.
Figure S2 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Authors: Narasimhan Vignesh , Wright Josephine A. , Churchill Michael , Wang Tongtong , Rosati Rachele , Lannagan Tamsin R.M. , Vrbanac Laura , Richardson Anne B. , Kobayashi Hiroki , Price Timothy , Tye Gayle X.Y. , Marker Julie , Hewett Peter J. , Flood Michael P. , Pereira Shalini , Whitney G. Adam , Michael Michael , Tie Jeanne , Mukherjee Siddhartha , Grandori Carla , Heriot Alexander G. , Worthley Daniel L. , Ramsay Robert G. , Woods Susan L.
Published: April 2023

Extended data peritonoid genomic analyses
Supplementary Figure S9 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S9
Figure S5 from Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Authors: Ladjohounlou Riad , Lozza Catherine , Pichard Alexandre , Constanzo Julie , Karam Jihad , Le Fur Pierre , Deshayes Emmanuel , Boudousq Vincent , Paillas Salomé , Busson Muriel , Le Blay Marion , Jarlier Marta , Marcatili Sara , Bardiès Manuel , Bruchertseifer Frank , Morgenstern Alfred , Torgue Julien , Navarro-Teulon Isabelle , Pouget Jean-Pierre
Published: April 2023

SUPPLEMENTARY FIG. S5. Signaling pathways activated in donor and recipient cells after exposure to 213Bi-anti-MISRII mAb alone or with MBCD.
Supplementary Data from Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Authors: Xing Deyin , Zheng Gang , Pallavajjala Aparna , Schoolmeester J. Kenneth , Liu Yuehua , Haley Lisa , Hu Yan , Liu Li , Logan Lisa , Lin Yuan , Pearce Kathryn E. , Sattler Christopher A. , Tsai Ya Chea , Vang Russell , Hung Chien-Fu , Wu T.-C. , Ronnett Brigitte M.
Published: April 2023

Supplementary Table and Figure legends
Table S3 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

List of 3351 genes differentially regulated between MDA PCa 144-13 and MDA PCa 144-4
Table S2 from Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Authors: Shi Donghua , Shi Yaoping , Kaseb Ahmed O. , Qi Xingxing , Zhang Yuan , Chi Jiachang , Lu Qing , Gao Huiping , Jiang Hua , Wang Huamao , Yuan Daijing , Ma Hong , Wang Hongyang , Li Zonghai , Zhai Bo
Published: April 2023

The previous therapies in patients on the study
Legend of Supplementary Figures from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

Legend of Supplementary Figures
Figure S7 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

Whole-genome copy number analysis of 3 MDA PCa PDXs
Figure S5 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Authors: Palanisamy Nallasivam , Yang Jun , Shepherd Peter D.A. , Li-Ning-Tapia Elsa M. , Labanca Estefania , Manyam Ganiraju C. , Ravoori Murali K. , Kundra Vikas , Araujo John C. , Efstathiou Eleni , Pisters Louis L. , Wan Xinhai , Wang Xuemei , Vazquez Elba S. , Aparicio Ana M. , Carskadon Shannon L. , Tomlins Scott A. , Kunju Lakshmi P. , Chinnaiyan Arul M. , Broom Bradley M. , Logothetis Christopher J. , Troncoso Patricia , Navone Nora M.
Published: April 2023

Whole-genome analysis of copy number changes in MDA PCa 146 PDXs
Supplementary Figure 1 from RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia
Authors: Anande Govardhan , Deshpande Nandan P. , Mareschal Sylvain , Batcha Aarif M.N. , Hampton Henry R. , Herold Tobias , Lehmann Soren , Wilkins Marc R. , Wong Jason W.H. , Unnikrishnan Ashwin , Pimanda John E.
Published: April 2023

Supplementary Figure 1, related to main Figure 1
Supplementary Material and Methods from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Authors: Pirker Christine , Bilecz Agnes , Grusch Michael , Mohr Thomas , Heidenreich Barbara , Laszlo Viktoria , Stockhammer Paul , Lötsch-Gojo Daniela , Gojo Johannes , Gabler Lisa , Spiegl-Kreinecker Sabine , Dome Balazs , Steindl Ariane , Klikovits Thomas , Hoda Mir Alireza , Jakopovic Marko , Samarzija Miroslav , Mohorcic Katja , Kern Izidor , Kiesel Barbara , Brcic Luka , Oberndorfer Felicitas , Müllauer Leonhard , Klepetko Walter , Schmidt Wolfgang M. , Kumar Rajiv , Hegedus Balazs , Berger Walter
Published: April 2023

Supplementary Material and Methods
Supplementary Figure S6 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Authors: Pirker Christine , Bilecz Agnes , Grusch Michael , Mohr Thomas , Heidenreich Barbara , Laszlo Viktoria , Stockhammer Paul , Lötsch-Gojo Daniela , Gojo Johannes , Gabler Lisa , Spiegl-Kreinecker Sabine , Dome Balazs , Steindl Ariane , Klikovits Thomas , Hoda Mir Alireza , Jakopovic Marko , Samarzija Miroslav , Mohorcic Katja , Kern Izidor , Kiesel Barbara , Brcic Luka , Oberndorfer Felicitas , Müllauer Leonhard , Klepetko Walter , Schmidt Wolfgang M. , Kumar Rajiv , Hegedus Balazs , Berger Walter
Published: April 2023

Supplementary Figure S6. Relation between TERT mRNA expression and MPM patient survival in the TCGA dataset.
Figure S5 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Authors: Misale Sandra , Fatherree Jackson P. , Cortez Eliane , Li Chendi , Bilton Samantha , Timonina Daria , Myers David T. , Lee Dana , Gomez-Caraballo Maria , Greenberg Max , Nangia Varuna , Greninger Patricia , Egan Regina K. , McClanaghan Joseph , Stein Giovanna T. , Murchie Ellen , Zarrinkar Patrick P. , Janes Matthew R. , Li Lian-Sheng , Liu Yi , Hata Aaron N. , Benes Cyril H.
Published: April 2023

Supplementary Figure 5